• Cardiology, Diabetes & Nephrology
    • Cardiology, Diabetes & Nephrology – London
    • Cardiology, Diabetes & Nephrology – Brazil
    • Cardiology, Diabetes & Nephrology – Canada
    • Cardiology, Diabetes & Nephrology – USA
    • Hatter Horizon Series
    • The 18th Malvern Diabetic Foot Conference
    • Previous Events
      • CDNATL 2019 – London
      • CDNATL 2019 – Brazil
      • CDNATL 2018
      • CDNATL 2017
      • CDNATL 2016
      • CDNATL 2015
      • CDNATL 2014
      • CDATL 2013
      • CDATL 2012
      • NATL 2012
      • CDATL 2011
      • CDATL 2010
      • NATL 2010
      • CATL 2009
      • NATL 2009
  • Cell Therapy
    • Cell Therapy at the Limits 2021
  • Oncology
    • Previous Events
      • Accelerating Cancer Immunotherapy 2017
      • OATL 2016
      • OATL 2015
      • OATL 2014
      • OATL 2012
      • OATL 2011
      • OATL 2010
      • UCL Frontiers of Oncology 2019
        • Haematology
        • Melanoma
        • Urology
        • Women’s Health
        • Lung Cancer
        • Gastrointestinal Oncology
  • Multiple Sclerosis
    • Multiple Sclerosis at the Limits 2021
    • Multiple Sclerosis Nurses at the Limits 2021
    • Previous events
      • Multiple Sclerosis Nurses at the Limits 2020
      • Multiple Sclerosis Nurses at the Limits 2019
      • MSATL 2018: Introduction
      • MSATL 2017: Introduction
  • About
    • Academic Founders
    • Independence
    • The Lancet
    • Support & Sponsorship
    • Delegate Invitations
  • Supporters
  • Archive
    • CDNATL 2019 – London
    • CDNATL 2019 – Brazil
    • Multiple Sclerosis at the Limits 2018
    • Multiple Sclerosis at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2020
    • Multiple Sclerosis Nurses at the Limits 2019
    • Hatter Horizon Series
      • Horizon GP Programme 2019
      • Hatter Horizon Series 2019
      • Hatter Horizon Series 2018
      • Hatter Horizon Series 2017
    • Cardiology, Diabetes & Nephrology at the Limits 2018
    • Accelerating Cancer Immunotherapy 2017
    • Oncology at the Limits 2017

Professor Christian Rolfo

He was born in Córdoba, Argentina in 1972; studied at the National University of Córdoba, graduating from the medical school in 1996. In 1998 he began his studies at the University of Milan, Italy. He got a scholarship for a project in Breast Cancer with the prestigious Dr. Luca Gianni, in one of the European reference centers for cancer, the National Cancer Institute of Milan. He worked for more than six years with him, dealing with Breast Cancer, Head and Neck Tumors, Sarcomas and Rare Tumors. He trained with Drs. Lisa Licitra and Paolo Casali, international experts in both areas. During this period he dealt with caring and Phase I Research Protocols, under the direction of Prof. Gianni. Obtained the European Oncology Board certification in 2003 with a thesis based on a Phase I trial with the combination of a new taxane and doxorubicin in Breast Cancer. Dr. Rolfo is also a Doctor of Medicine and Surgery at the University of Catania, Italy, with a thesis based on a Phase Ib trial and pharmacokinetics of BMS 184476 and anthracyclines in solid tumors. In 2004 he moved to Palma de Mallorca, Spain, where he worked in the Oncology Unit of the Clinica Rotger until September 2012.

It is here where he began his work in the Spanish Group for Lung Cancer, under the direction of Professor Rafael Rosell, actively involved in studies of molecular biology and clinical research in lung cancer. In 2009 obtained the PhD degree and Doctor Europaeus in Clinical and Experimental Oncology Research with cum laude from the University of Palermo, Italy, for the thesis: The relationship between metabolic activity (SUV max) by 18-FDG PET and histology, stage, EGFR mutations and survival in patients with NSCLC, under the direction of Professor Antonio Russo and Professor Rafael Rosell.

Since October 2012 is senior staff member in the Department of Oncology as associate Professor at the University Hospital Antwerp, Antwerp University in Belgium, headed by Professor Marc Peeters . Currently he is Head of the Phase I – Early Clinical Trials Unit, and Director of the Clinical Trails Management Program. He is focused on Clinical Research, Drug Development and Resistance.

He is actively working in a research program of Liquid Biopsies in Lung Cancer, specifically in exosomes isolation and circulating tumor DNA.

He completed his training in organization in Phase I at Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX (Visiting Professor Program) with Prof. David Hong. Dr. Rolfo is the author of numerous papers published in various journals including New England Journal of Medicine, Annals of Oncology, Lancet Oncology, Oncotarget, Translational oncology, Journal of Clinical Oncology, among others. It is also a speaker at national and international forums Lung Cancer.

Professor Rolfo is part of the working group of the ETOP mesothelioma (European Platform Thoracic Oncology), led by Prof. Rolf Stahel. He was also member of the membership Board of IALSC (International Association for the Study of Lung Cancer) and currently is a member in the Educational Committee (IALSC) and from 2016 he is part of Membership Committe at ESMO. He is member of prestigious Societies including AACR, BACR, EACR, and ASCO.

He served as a Scientific Board member of the Drug Development Group for ESMO meetings in 2016 and 2018, and is currently appointed as a Scientific Board Committee member at the European School of Oncology (ESO) for 2017-2019 period.

Prof. Rolfo also obtained the Master degree in Business Health Administration by Polytechnic University of Valencia, Spain in 2010.

In February 2011 he was appointed as visiting professor in Medical Oncology by the Molecular and Clinical Genetic Oncology Unit at the Interdepartmental Center of Research in Clinical Oncology, School of Medicine, University of Palermo (Italy).

In addition, he has teaching duties at the University of the Balearic Islands. From 2014, he has been a guest Professor at Palermo University and Director of Investigational Cancer Therapeutics Fellowship in Drug Development: Clinical and Experimental, at Antwerp University Hospital, Belgium. He is also involved in ESMO and IASLC education projects (ESMO SLACOM workshop in Clinical Trials and Clinical Research in Lung Cancer respectively) and chair of EORTC PAMM Group in Antwerp on February 2016. Currently, Professor Rolfo is Deputy Editor and Section Editor for Investigational Therapeutics in Critical Reviews in Oncology Hematology, Section Editor of Translational Research at the Belgian Journal of Medical Oncology and on the editorial team at the ESMO Open Journal Cancer Horizons, and in Lung Cancer (Elsevier)

« Dr David Meek
Professor Karen Sliwa »

Cardiology, Diabetes & Nephrology at the Limits Canada
Wednesday, 3 & Thursday, 4 March 2021, Virtual Meeting

Cardiology, Diabetes & Nephrology at the Limits 2021
Monday, 12 & Tuesday, 13 April 2021, Virtual Meeting

The 18th Malvern Diabetic Foot Conference
Wednesday, 12 – Friday, 14 May 2021, Malvern, UK

Multiple Sclerosis Nurses
at the Limits

Friday, 10 & Saturday, 11 September 2021, London, UK

Multiple Sclerosis at the Limits
Monday, 13 & Tuesday, 14 September 2021, London, UK

Hatter Horizon GP Meeting
Monday, 1 November 2021
London, UK

Cell Therapy at the Limits 2021
Monday, 8 & Tuesday, 9 November 2021, London, UK

Hatter Horizon Series
Monday, 22 November 2021, London, UK

Cardiology, Diabetes & Nephrology at the Limits Brazil
Friday, 10 - Saturday, 11 December 2021, São Paulo, Brazil

Policy links

  • Medical Disclaimer
  • Disclosure
  • E-mail Policy
  • Privacy Policy
  • Anti-spam Policy
  • Disclaimer
  • External Links Policy
  • Terms of use
  • Contact
  • The Lancet
  • UCL
  • UCT
  • Brigham & Women’s Hospital
  • The University of Campinas
© 2021 At the Limits Ltd.
This site uses cookies More info